Meghívásos bevonás
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease
2025-522001-38-00· 2. fázis· Mirador Therapeutics Inc.· Forrás
Fut, nem toboroz
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07424144· 3. fázis· Sanofi· Forrás
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336· 2. fázis· Genentech, Inc.· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
NCT06975722· 2. fázis· Sanofi· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
NCT06958536· 2. fázis· Sanofi· Forrás
Toboroz
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· 2. fázis· AstraZeneca· Forrás
Meghívásos bevonás
Long-term Safety and Tolerability of BHV-7000
NCT06443463· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
NCT06094010· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013· 2. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás